Drug intelligence / Profile preview

FLASH-002

Development stage: Unknown
Lead developer: Flashpoint Therapeutics
Modality: Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

FLASH-002 is a nanomedicine-based immunotherapy developed by Flashpoint Therapeutics. It acts as an OX-40 (CD134) agonist, designed to stimulate and activate T cells to enhance anti-tumor immune responses. The drug utilizes Flashpoint's proprietary precision-engineered structural nanomedicine platform, which allows for the co-delivery of optimized combinations of therapeutic payloads directly to individual cells. FLASH-002 is currently in clinical development for the treatment of various cancers, representing a generation of therapies that aim to improve the efficacy and safety of immune-stimulating agents through targeted delivery.

Targets

CD28 (Cluster of Differentiation 28)

Beyond the preview

Go deeper on FLASH-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FLASH-002.

Explore the full profile